HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

LY 465608

a nonthiazolidinedione agonist of both PPAR-alpha and PPAR-gamma of Ligand Pharm. and Eli Lilly

Also Known As:

LY 465,608; LY-465,608; LY-465608; LY465608

Networked: 3 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- LY 465608: 3

Experts

1.	Kauffman, Raymond F: 2 articles (05/2002 - 04/2002)
2.	Baker, Thomas K: 1 article (04/2007)
3.	Calley, John N: 1 article (04/2007)
4.	Gao, Hong: 1 article (04/2007)
5.	Guo, Yin: 1 article (04/2007)
6.	Halstead, Bartley W: 1 article (04/2007)
7.	Huffman, Melanie: 1 article (04/2007)
8.	Irizarry, Armando R: 1 article (04/2007)
9.	Jolly, Robert A: 1 article (04/2007)
10.	Li, Shuyu: 1 article (04/2007)

Related Diseases

1.	Metabolic Syndrome (Dysmetabolic Syndrome X) 04/01/2002 - "A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models."
2.	Insulin Resistance 04/01/2002 - "A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models."
3.	Hyperglycemia 04/01/2002 - "A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models."
4.	Necrosis 04/01/2007 - "Repeat-dose nonclinical safety studies of LY465608 revealed abnormities in mitochondrial morphology and evidence of single-cell necrosis following 30 days of dosing exclusively in dogs, but not in rats. "
5.	Type 2 Diabetes Mellitus (MODY) 04/01/2002 - "Overall, these studies demonstrate that LY465608 beneficially impacts multiple facets of type 2 diabetes and associated cardiovascular risk, including those facets involved in the development of micro- and macrovascular complications, which are the major sources for morbidity and mortality in these patients." 04/01/2002 - "A novel nonthiazolidinedione dual peroxisome proliferator- activated receptor (PPAR)-alpha/gamma agonist, LY465608, was designed to address the major metabolic disturbances of type 2 diabetes. "

Related Drugs and Biologics

1.	PPAR alpha
2.	Peroxisome Proliferator-Activated Receptors (PPAR)
3.	Apolipoproteins

Related Therapies and Procedures

1.	Therapeutics